Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease
The efficacy and safety of IFX-BS after NMS are high. In addition, its trough concentration is serologically non-inferior to baseline values.
Authors
- Shinya Ashizuka (ORCID: https://orcid.org/0000-0003-2530-760X)
- Takashi Hisabe (ORCID: https://orcid.org/0000-0001-7308-1030)
- Fumihito Hirai (ORCID: https://orcid.org/0000-0002-5493-5675)
- Noritaka Takatsu (ORCID: https://orcid.org/0000-0002-1967-5169)
- Yoichiro Ono (ORCID: https://orcid.org/0000-0003-2492-8041)
- Takao Kanemitsu (ORCID: https://orcid.org/0000-0003-0581-2211)
- Shigeyoshi Yasukawa (ORCID: https://orcid.org/0000-0002-7421-2706)
- Teruyuki Takeda (ORCID: https://orcid.org/0000-0001-5682-9588)
- Masaki Miyaoka (ORCID: https://orcid.org/0000-0002-4166-2372)
- Akihiro Koga (ORCID: https://orcid.org/0000-0003-1546-1152)
- Ryohei Nomaru (ORCID: https://orcid.org/0009-0005-1058-5166)
- So Imakiire (ORCID: https://orcid.org/0000-0002-7076-4335)
- Hisatomi Arima (ORCID: https://orcid.org/0000-0002-2064-2014)
- Hiroyuki Mikumo (ORCID: https://orcid.org/0009-0006-8321-6051)
- Atsushi Takahashi (ORCID: https://orcid.org/0009-0004-2698-7920)
- Eri Yamauchi (ORCID: https://orcid.org/0009-0008-4656-385X)
Institutions
- Fukuoka University (JP)
Publication Details
- Journal
- Intestinal Research
- Published
- 2025-11-27
- DOI
- https://doi.org/10.5217/ir.2025.00118
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00